Alnylam Pharmaceuticals Valuation
| ALNY Stock | USD 244.89 1.91 0.77% |
At this time, the firm appears to be overvalued. Alnylam Pharmaceuticals shows a prevailing Real Value of $204.08 per share. The current price of the firm is $244.89. Our model approximates the value of Alnylam Pharmaceuticals from analyzing the firm fundamentals such as Return On Equity of -15.01, profit margin of (0.16) %, and Current Valuation of 30.11 B as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Alnylam Pharmaceuticals' valuation include:
Price Book 976.2668 | Enterprise Value 30.1 B | Enterprise Value Ebitda 204.8549 | Price Sales 15.0784 | Forward PE 909.0909 |
Overvalued
Today
Please note that Alnylam Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Alnylam Pharmaceuticals is based on 3 months time horizon. Increasing Alnylam Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Alnylam Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Alnylam Stock. However, Alnylam Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 244.89 | Real 204.08 | Target 229.39 | Hype 244.06 | Naive 242.96 |
The intrinsic value of Alnylam Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Alnylam Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Alnylam Pharmaceuticals helps investors to forecast how Alnylam stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Alnylam Pharmaceuticals more accurately as focusing exclusively on Alnylam Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Alnylam Pharmaceuticals' intrinsic value based on its ongoing forecasts of Alnylam Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Alnylam Pharmaceuticals' closest peers.
Alnylam Pharmaceuticals Cash |
|
Alnylam Valuation Trend
Analysing the historical paterns of Alnylam Pharmaceuticals' enterprise value and its market capitalization is a good way to estimate and gauge the value of Alnylam Pharmaceuticals over time and is usually enough for investors to make rational market timing decisions.
Alnylam Revenue by Product
Alnylam Pharmaceuticals Total Value Analysis
Alnylam Pharmaceuticals is presently estimated to have valuation of 30.11 B with market capitalization of 31.59 B, debt of 2.68 B, and cash on hands of 2.27 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Alnylam Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
30.11 B | 31.59 B | 2.68 B | 2.27 B |
Alnylam Pharmaceuticals Investor Information
About 98.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.62. Alnylam Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to Alnylam Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Alnylam Pharmaceuticals may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Alnylam Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Alnylam Pharmaceuticals has an asset utilization ratio of 47.74 percent. This suggests that the Company is making $0.48 for each dollar of assets. An increasing asset utilization means that Alnylam Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Alnylam Pharmaceuticals Ownership Allocation
Alnylam Pharmaceuticals holds a total of 128.98 Million outstanding shares. The majority of Alnylam Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alnylam Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alnylam Pharmaceuticals. Please pay attention to any change in the institutional holdings of Alnylam Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Alnylam Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 1.83 B. Net Loss for the year was (440.24 M) with profit before overhead, payroll, taxes, and interest of 868.6 M.About Alnylam Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Alnylam Pharmaceuticals. We calculate exposure to Alnylam Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Alnylam Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1.5 B | 1.6 B | |
| Pretax Profit Margin | (0.24) | (0.25) | |
| Operating Profit Margin | (0.15) | (0.16) | |
| Net Loss | (0.24) | (0.25) | |
| Gross Profit Margin | 0.83 | 0.96 |
Alnylam Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 124.9 M | |
| Forward Price Earnings | 909.0909 |
Alnylam Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Alnylam Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Alnylam we look at many different elements of the entity such as Alnylam's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Alnylam Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Alnylam Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Alnylam Pharmaceuticals' worth.Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.